Croissy-Beaubourg and Montpellier, March 18, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announced today it has moved into its new Marne-La-Vallée facility, in the Paris area.
Theradiag ‘s new location offers over 3,200 square meters of R&D and production laboratories, and office space. This represents a 60% gain in floor space with no significant increase in rental costs. Two thirds of the increase in space is allocated to R&D and production facilities, which will allow the Company to increase the volume of production and automation of its proprietary products.
“We anticipate that there will be a significant increase in the demand for our in-house products, especially our LISA TRACKER kits to monitor biotherapies. We wanted to insure that we had the space we need to support our ambitions and meet the demands of future growth. In our new facility, we will be able to multiply the production of our LISA TRACKER kits by 10” commented Michel Finance, Chief Executive Officer of Theradiag.
“Our new headquarters are significantly larger than before, and offer room for further expansion should we require to accommodate an additional increase in production and R&D efforts. With this new facility, Theradiag is now playing in a new league.” concludes Michel Finance.
All of the company’s business-line activities across the entire value chain, from R&D to industrialization, production, certification, distribution and marketing, are located on one single site. By bringing closer together administrative, marketing, research, and production staff, the new headquarters foster greater collaboration between teams and create a more innovative environment.
The relocation of the Company was conducted in two phases over the first quarter of 2015, without any interruption in the production and distribution of Theradiag’s IVD and theranostics products. All teams are now located on the new site and fully operational.
Theradiag will invite its shareholders on its new grounds during the Shareholders’ Annual Meeting of April 16, 2015. Details to follow.
Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer and HIV/AIDS. Theradiag is thus participating in the development of “customized treatment”, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 70 employees.
For more information about Theradiag, please visit our website: www.theradiag.com
TheradiagInvestor RelationsNathalie Trepo+33 1 64 62 10 12
NewCapFinancial communications/ investor relationsValentine Brouchot/Pierre Laurent
+33 1 44 71 94 94
Alize RPPressCaroline Carmagnol+33 6 64 18 99 59